Cannabigerol (CBG) isolate lacks the mainstream appeal and understanding that CBD has, but at Sanobiotec, we have no doubt that this major cannabinoid will soon play a significant role in the life of the everyday consumer.
CBG will soon be more of a household name than it is right now, we just know it.
Before long, we expect to see this major cannabinoid CBG used for a range of different purposes, such as CBG for skincare, and for it to be taken in a variety of user-friendly ways, such as in CBG gummies.
Well, CBG demonstrates a wide variety of potential benefits for the health, wellness and medicinal industries.
The bioactive ingredient within the CBG cannabinoid molecule activates both CB1 and CB2 cannabinoid receptors in the body, making its potential particularly interesting for application as an antibacterial, anti microbial, antioxidant and anti-inflammatory agent.
It certainly has properties which suggest its effectiveness for these applications. Cannabigerolic acid (CBGA) may help diabetic patients in combating some of the disease’s complications and comorbidities such as cardiovascular disease.
In fact, cannabigerolic acid was found by some pieces of research and development, to greatly inhibit the enzyme aldose reductase which is a major contributor to the oxidative stress that can lead to heart problems.
As with all the major and minor cannabinoids we work with, we like to keep an eye on all the relevant and recent research into each compound.
In terms of cannabigerol, recent research has looked to explore its effectiveness and potential application to things such as:
Digestion and intestines – other minor and major cannabinoids have positive effects in these areas.
Inflammation – CBG cannabinoid has already been shown to have huge potential as an anti-inflammatory.
Nausea – being able to have a non-toxic solution to nausea is top of many people’s agendas. CBG could provide this.
Pain – minor cannabinoids have been shown to get to work quickly in reducing and limiting the neuropathic signals which cause pain.
The CBG cannabinoid molecule and the associated CBG cannabinoid effects are becoming more widely understood across the industry.
The same is true across the industries Sanobiotec supplies, with demand increasing as more benefits are studied and confirmed.
Where there are still questions, there is now plenty of research and development geared towards answering those questions, and we really don’t think it will be too long at all before minor cannabinoid CBG begins to earn some of the recognition that major cannabinoid cbd does for its effectiveness across a wide range of applications.
The European Commission added Cannabigerol (CBG) as a legal ingredient to CosIng – the database for information on cosmetic substances and ingredients. This means, that European personal care and cosmetics manufacturers can use CBG in their products with approval from the market regulator.
This is a summary of the research interests for each cannabinoid being discussed. These statements have not been evaluated by regulatory bodies such as Food and Drug Administration. This ingredient is not intended to diagnose, treat, cure or prevent any disease. Sanobiotec has provided this summary solely to provide the reader with information on the types of studies being conducted on cannabinoids.
Sources:
1. Farha et al. Uncovering the Hidden Antibiotic Potential of Cannabis.ACS Infectious Diseases. March 2020; 6, 3, 338-346.
2. Aqawi et al. Cannabigerol Prevents Quorum Sensing and Biofilm Formation of Vibrio harveyi.Front Microbiol. May 2020; 11(article 858).
3. Baek et al. Boron trifluoride etherate on silica-A modified lewis acid reagent (VII). Antitumor activity of cannabigerol against human oral epitheloid carcinoma cells.Arch. Pharm. Res. 21, 353, June 1998.
4. Beak et al.Synthesis and antitumor activity of cannabigerol. Arch. Pharm. Res. 19, 228–230, June 1996.
5. Brierley et al. Chemotherapy‐induced cachexia dysregulates hypothalamic and systemic lipoamines and is attenuated by cannabigerol.J. of Cachexia, Scarcopenia and Muscle. April 2019; Volume10 (4): 844-859.
6. Borrelli et al. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease.Biochem Pharmacol. May 2013; 1;85(9):1306-16.
7. Borrelli et al. Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis- derived non-psychotropic cannabinoid. Carcinogenesis. September 2014; vol.35 no.12 pp.2787–2797.
8. Colasanti. A Comparison of the Ocular and Central Effects of Δ9-Tetrahydrocannabinol and Cannabigerol.Journal of Ocular Pharmacology and Therapeutics. March 2009; Vol. 6, No. 4.
9. Colasanti et al. Intraocular pressure, ocular toxicity and neurotoxicity after administration of cannabinol or cannabigerol.Exp Eye Res. September 1984; 39(3):251-9.
10. Echeverry C et al. A comparative in vitro study of the neuroprotective effect induced by cannabidiol, cannabigerol, and their respective acid forms: relevance of the 5-HT1A receptors.Neurotox Res. 2021 Apr; 39(2):335-348.
11. Fellous et al. Phytocannabinoids promote viability and functional adipogenesis of bone marrow-derived mesenchymal stem cells through different molecular targets.Biochemical Pharmacology. May 2020; Volume 175: 113859.
12. Gugliandolo et al. In Vitro Model of Neuroinflammation: Efficacy of Cannabigerol, a Non-Psychoactive Cannabinoid.Int J Mol Sci. July 2018; 19(7): 1992.
13. Lah TT et al. Cannabigerol is a potential therapeutic agent in a novel combined therapy for glioblastoma.Cells. 10(2): 340, February 2021.
14. Mammana et al. Could the Combination of Two Non-Psychotropic Cannabinoids Counteract Neuroinflammation? Effectiveness of Cannabidiol Associated with Cannabigerol.Medicina (Kaunas). November 2019; 55(11): 747.
15. Nachnani R et al.The pharmacological case for cannabigerol CBG. J Pharmacol Exp Therapeut. February 2021; 376(2): 204-212.
16. Olah et al. Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment.Exp Dermatol. September 2016; 25(9):701-7.
17. Pagano E et al. Efficacy of combined therapy with fish oil and phytocannabinoids in murine intestinal inflammation.Phytother Res. January 2021 35(1): 517-529.
18. Pagano E et al. Effect of non-psychotropic plant-derived cannabinoids on bladder contractility: focus on cannabigerol.Natural Prod Commun: 10(6): 1009-1012, June 2015.
19. Schoeman R et al. Cannabinoid combination induces cytoplasmic vacuolation in MCF-7 breast cancer cells.Molecules. 25(20): 4682, October 2020.
20. Stone NL et al. Protective effects of cannabidivarin and cannabigerol on cells of the blood-brain barrier under ischemic conditions. Cannabis Cannabinoid Res. 2021 Mar 17. doi: 10.1089/can.2020.0159.
21. Stahl V et al.Comparison of Efficacy of Cannabinoids versus Commercial Oral Care Products in Reducing Bacterial Content from Dental Plaque: A Preliminary Observation. Cureus 12(1): e6809, January 2020.
22. US8481085.Pharmaceutical compositions comprising cannabigerol. 2013.
23. Valdeolivas et al.Neuroprotective properties of cannabigerol in Huntington’s disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics. January 2015;12(1):185-99.
24. Vasudevan et al. Cannabinoids infused mouthwash products are as effective as chlorhexidine on inhibition of total-culturable bacterial content in dental plaque samples. Journal of Cannabis Research. June 2020; 2, 20 (2020).
25. WO2012160358. Cannabinoids for use in the treatment of neuropathic pain.2011.
26. WO2018144637. Cannabinoid containing complex mixtures for the treatment of mast cell-associated or basophil mediated inflammatory disorders.2018.
